• Hsin-Sung Chiu, Meng-Ju Melody Tsai, Ting-Ming Wang, Ni-Chung Lee, and Yi-Ching Tung.
• Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
• J Formos Med Assoc. 2024 Oct 6.

AbstractHypophosphatemic rickets is a rare metabolic bone disease caused by renal phosphate wasting, leading to impaired bone mineralization. We present a case of a boy with fibroblast growth factor 23 (FGF23)-related hypophosphatemic rickets who did not achieve callus consolidation after six months of conventional therapy with phosphate and active vitamin D following corrective osteotomy. After one month of therapy with an FGF23 antibody (burosumab), the patient demonstrated significant improvement and no longer required a walking aid. Following six months of burosumab therapy, the bone had nearly fully healed. This report is the first to address the short-term use of burosumab therapy to promote bone healing after orthopedic surgery. Our findings further emphasize the clinical advantages and short-term applications of burosumab in FGF23-related hypophosphatemic diseases, especially for patients undergoing orthopedic surgery.Copyright © 2024 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

3 keywords...

hide…